An estimated 44% of patients with advanced lymphoma are still alive four years after receiving a single infusion of Yescarta (axicabtagene ciloleucel) for their disease. The new long-term survival data were presented by Gilead Sciences Inc at the annual meeting of the American Society of Hematology (ASH), further illustrating the efficacy of the chimeric antigen receptor (CAR) T cell therapy class.
